We are committed to serving the best interests of our shareholders.

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary TESARO Announces Positive Top-Line Results From Quadra Trial of ZEJULA®
Results demonstrate ZEJULA activity beyond patients with BRCA mutations in late-line ovarian cancer treatment setting QUADRA data accepted for presentation at 2018 ASCO annual meeting Data intended to support label expansion with biomarker in the treatment setting WALTHAM, Mass.
View HTML
Toggle Summary TESARO to Announce First-Quarter 2018 Financial Results on May 3, 2018
WALTHAM, Mass. , April 19, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) will announce first-quarter 2018 financial results on Thursday, May 3, 2018 , after the close of the U.S. financial markets. TESARO’s senior management team will host a conference call and live audio webcast at 4:15 p.m.
View HTML
Toggle Summary TESARO to Receive 2018 Partnership Award at CancerCare® Gala
TESARO to Receive 2018 Partnership Award at Cancer Care® Gala - NEW YORK, April 19, 2018 – Cancer Care ®, the leading national nonprofit organization providing free, professional support services to anyone affected by cancer, announced that TESARO will receive their 2018 Partnership
View HTML
Toggle Summary TESARO Summarizes TSR-042 Clinical Data Presented at AACR
Activity of TSR-042 (anti-PD-1 antibody) monotherapy demonstrated in patients with MSI-high endometrial and non-small cell lung cancers Data support unique and convenient dosing schedule Regulatory submission for TSR-042 for MSI-high tumors planned in 2H 2019 CHICAGO , April 16, 2018 (GLOBE
View HTML
Toggle Summary TESARO and Medison Enter Into Exclusive Distribution Agreement to Commercialize ZEJULA® in Israel
Agreement covers all indications for ZEJULA, excluding prostate cancer ZUG, Switzerland and PETACH TIKVA, Israel, April 11, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, and Medison Pharma Ltd. , Israel's leading commercial partner for
View HTML
Toggle Summary Data From TOPACIO Trial Reported at SGO Demonstrates Compelling Clinical Activity of ZEJULA in Combination With an Anti-PD-1 Antibody in Patients With Platinum Resistant/Refractory Ovarian Cancer
Efficacy of niraparib in combination with an anti-PD-1 mAb surpasses historical efficacy benchmarks for PD-1 or PARP monotherapies in difficult-to-treat types of ovarian cancer, regardless of biomarker status Potential approach to reduce incidence of Grade 3 or 4 thrombocytopenia identified based
View HTML
Toggle Summary TESARO Announces Data Presentations at the 2018 American Association for Cancer Research Annual Meeting
WALTHAM, Mass. , March 14, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that data for ZEJULA, TSR-042 (anti-PD-1 antibody) and the company’s immuno-oncology portfolio will be presented at the 2018 American Association for Cancer
View HTML
Toggle Summary TESARO Announces Participation at Two Investor Conferences
WALTHAM, Mass. , March 01, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in two upcoming investor conferences. The two conferences are:       The Barclays Global Healthcare Conference at the Loews Hotel in
View HTML
Toggle Summary TESARO Announces Fourth-Quarter and Full-Year 2017 Operating Results
ZEJULA is the #1 PARP inhibitor for women with ovarian cancer in the U.S. 2017 ZEJULA ® net sales totaled $109 million during first nine months of commercial launch Focused clinical development program for niraparib in ovarian cancer is advancing in first-line and platinum-resistant settings
View HTML
Toggle Summary TESARO Announces Collaboration to Evaluate Combination of ZEJULA® (Niraparib) and Anti-PD-L1 Cancer Immunotherapy in Metastatic Bladder Cancer
WALTHAM, Mass. , Feb. 26, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that it has entered into a clinical collaboration with Genentech, a member of the Roche Group , to evaluate the combination of the PD-L1 antibody
View HTML